{"id":390900,"date":"2017-09-25T00:00:00","date_gmt":"2017-09-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0028-2017-biopharma-unipolar-depression-treatment-algorithms-claims-data-analysis-major-depressive-disorder-us\/"},"modified":"2026-04-25T11:39:28","modified_gmt":"2026-04-25T11:39:28","slug":"algocg0028-2017-biopharma-unipolar-depression-treatment-algorithms-claims-data-analysis-major-depressive-disorder-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0028-2017-biopharma-unipolar-depression-treatment-algorithms-claims-data-analysis-major-depressive-disorder-us\/","title":{"rendered":"Unipolar Depression | Treatment Algorithms: Claims Data Analysis | Major Depressive Disorder | US | 2017"},"content":{"rendered":"<p>MARKET OUTLOOK\u00a0<br \/>\nMDD is a highly drug-treated condition that utilizes an array of drug classes, including, but not limited to, SSRI , SNRI s, and\u2014as adjunctive therapies\u2014atypical antipsychotics. Even though the MDD drug market is highly entrenched with generic therapies, MDD patients\u2019 heterogeneous response to antidepressants and\/or atypical antipsychotics afford branded drugs (, Trintellix [Lundbeck\/Takeda], Rexulti [Otsuka Pharmaceuticals\/Lundbeck]) the opportunity to be introduced into the treatment paradigm, often as later-line therapies. Given MDD \u2019s highly crowded and competitive landscape, it is valuable for drug marketers and developers to understand how MDD patients are being treated using claims data.\u00a0<br \/>\nQUESTIONS ANSWERED\u00a0<\/p>\n<p>What patient share do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed MDD patients?\u00a0<br \/>\nHow have antidepressants and atypical antipsychotics been integrated into the treatment algorithm?\u00a0<br \/>\nWhat proportion of MDD patients receive drug therapy within one year of diagnosis, and how quickly?\u00a0<br \/>\nWhat percentage of patients progress to later lines of therapy within one year of diagnosis?\u00a0<br \/>\nWhat percentage of MDD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?\u00a0<br \/>\nWhat are the product-level compliance and persistency rates among drug-treated patients with MDD ?\u00a0<\/p>\n<p>PRODUCT DESCRIPTION\u00a0<br \/>\nTreatment Algorithms: Claims Data Analysis (Truven) provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390900","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-unipolar-depression","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390900\/revisions"}],"predecessor-version":[{"id":394024,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390900\/revisions\/394024"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}